- Home
- KRNT vs MLTX Comparison
KRNT vs MLTX Comparison
Compare KRNT & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRNT
- MLTX
- Stock Information
- Founded
- KRNT 2002
- MLTX 2021
- Country
- KRNT Israel
- MLTX Switzerland
- Employees
- KRNT N/A
- MLTX N/A
- Industry
- KRNT Industrial Machinery/Components
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- KRNT Industrials
- MLTX Health Care
- Exchange
- KRNT Nasdaq
- MLTX Nasdaq
- Market Cap
- KRNT 629.8M
- MLTX 595.6M
- IPO Year
- KRNT 2015
- MLTX N/A
- Fundamental
- Price
- KRNT $14.26
- MLTX $9.92
- Analyst Decision
- KRNT Strong Buy
- MLTX Buy
- Analyst Count
- KRNT 5
- MLTX 9
- Target Price
- KRNT $31.40
- MLTX $37.63
- AVG Volume (30 Days)
- KRNT 386.4K
- MLTX 5.7M
- Earning Date
- KRNT 11-05-2025
- MLTX 11-07-2025
- Dividend Yield
- KRNT N/A
- MLTX N/A
- EPS Growth
- KRNT N/A
- MLTX N/A
- EPS
- KRNT N/A
- MLTX N/A
- Revenue
- KRNT $207,639,000.00
- MLTX N/A
- Revenue This Year
- KRNT $5.50
- MLTX N/A
- Revenue Next Year
- KRNT $9.04
- MLTX N/A
- P/E Ratio
- KRNT N/A
- MLTX N/A
- Revenue Growth
- KRNT N/A
- MLTX N/A
- 52 Week Low
- KRNT $12.78
- MLTX $5.95
- 52 Week High
- KRNT $34.29
- MLTX $62.75
- Technical
- Relative Strength Index (RSI)
- KRNT 50.42
- MLTX 28.84
- Support Level
- KRNT $14.05
- MLTX $9.37
- Resistance Level
- KRNT $15.28
- MLTX $10.40
- Average True Range (ATR)
- KRNT 0.58
- MLTX 0.54
- MACD
- KRNT 0.09
- MLTX 1.66
- Stochastic Oscillator
- KRNT 53.30
- MLTX 52.58
About KRNT Kornit Digital Ltd.
Kornit Digital Ltd develops, designs and markets digital printing solutions for the world-wide printed textile industry. The company focuses on its DTG and DTF segments of the printed textile industry. Its solutions include digital printing systems, ink and other consumables, associated software and value-added services that allow for large-scale printing of short runs of complex images and designs directly on finished garments and fabrics. It generates revenue from sales of systems, ink and other consumables and service including software subscriptions The company geographically operates in U.S., EMEA, Asia Pacific and other countries. It derives maximum revenue from U.S.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.